Symbols / GNPX
GNPX Chart
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.62M |
| Enterprise Value | 3.94M | Income | -16.77M | Sales | — |
| Book/sh | 0.77 | Cash/sh | 0.49 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -1.02 | PEG | — |
| P/S | — | P/B | 2.90 | P/C | — |
| EV/EBITDA | -0.24 | EV/Sales | — | Quick Ratio | 0.43 |
| Current Ratio | 0.67 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1261.62 | EPS next Y | -2.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-05-12 16:00 | ROA | -273.31% |
| ROE | -14.01% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.63M |
| Shs Float | 2.27M | Short Float | 22.80% | Short Ratio | 0.35 |
| Short Interest | — | 52W High | 55.00 | 52W Low | 1.71 |
| Beta | -0.79 | Avg Volume | 723.94K | Volume | 6.36M |
| Target Price | — | Recom | None | Prev Close | $2.27 |
| Price | $2.22 | Change | -2.20% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.22
Latest analyst target
3. DCF / Fair value
$-112.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.22
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-25 | init | HC Wainwright & Co. | — → Buy | $10 |
- Japan, EU patents shield gene therapy combo for small cell lung cancer - Stock Titan Mon, 23 Feb 2026 13
- Genprex stock jumps on Japan, Europe patent approvals - Investing.com Mon, 23 Feb 2026 17
- Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative hu, 15 Jan 2026 08
- Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Sahm Fri, 09 Jan 2026 08
- Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - PR Newswire ue, 28 Oct 2025 07
- Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail Sat, 10 Jan 2026 08
- Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks Mon, 23 Feb 2026 13
- Genprex, Inc. Announces $75 Million Stock Offering - TradingView Fri, 21 Nov 2025 08
- Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus Mon, 23 Feb 2026 14
- Genprex (GNPX) Shares Jump 41% After Hours Following New Cancer Therapy Data - Benzinga Wed, 15 Oct 2025 07
- Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release | GNPX Stock News - Quiver Quantitative Wed, 03 Dec 2025 08
- Genprex Announces Reverse Stock Split Amendment - The Globe and Mail Sat, 18 Oct 2025 07
- Genprex stock tumbles after announcing $3.4 million registered offering - Investing.com ue, 28 Oct 2025 07
- New Australian patent move backs gene therapy in lung cancer trial - Stock Titan ue, 10 Feb 2026 08
- Genprex (NASDAQ: GNPX) reports REQORSA + alectinib increased apoptosis in ALK+ NSCLC - Stock Titan ue, 28 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9000 | — | — | Stock Award(Grant) at price 0.00 per share. | LONGNECKER BRENT MICHAEL | Director | — | 2025-12-22 00:00:00 | D |
| 1 | 28500 | — | — | Stock Award(Grant) at price 0.00 per share. | BERGER MARK STANLEY | Officer | — | 2025-12-22 00:00:00 | D |
| 2 | 45000 | — | — | Stock Award(Grant) at price 0.00 per share. | CONFER RYAN M. | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 3 | 9000 | — | — | Stock Award(Grant) at price 0.00 per share. | MORENO TOSCANO JOSE ANTONIO | Director | — | 2025-12-22 00:00:00 | D |
| 4 | 9000 | — | — | Stock Award(Grant) at price 0.00 per share. | WILSON WILLIAM R. JR | Director | — | 2025-12-22 00:00:00 | D |
| 5 | 4750 | nan | — | — | LONGNECKER BRENT MICHAEL | Director | — | 2024-12-05 00:00:00 | D |
| 6 | 18250 | nan | — | — | BERGER MARK STANLEY | Officer | — | 2024-12-05 00:00:00 | D |
| 7 | 29375 | nan | — | — | CONFER RYAN M. | Chief Executive Officer | — | 2024-12-05 00:00:00 | D |
| 8 | 4750 | nan | — | — | MORENO TOSCANO JOSE ANTONIO | Director | — | 2024-12-05 00:00:00 | D |
| 9 | 4750 | nan | — | — | WILSON WILLIAM R. JR | Director | — | 2024-12-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -21.17M | -31.04M | -23.81M | -20.65M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.11M | -30.86M | -23.74M | -20.66M |
| ReconciledDepreciation | 6.69K | 15.00K | 25.57K | 22.53K |
| EBITDA | -21.17M | -31.04M | -23.81M | -20.65M |
| EBIT | -21.17M | -31.06M | -23.83M | -20.67M |
| NetInterestIncome | 63.57K | 215.11K | 90.10K | 5.13K |
| InterestIncome | 63.57K | 215.11K | 90.10K | 5.13K |
| NormalizedIncome | -21.11M | -30.86M | -23.74M | -20.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.11M | -30.86M | -23.74M | -20.66M |
| TotalExpenses | 21.17M | 31.06M | 23.83M | 20.67M |
| TotalOperatingIncomeAsReported | -21.17M | -31.06M | -23.83M | -20.67M |
| DilutedAverageShares | 4.01M | 1.37M | 1.20M | 1.18M |
| BasicAverageShares | 4.01M | 1.37M | 1.20M | 1.18M |
| DilutedEPS | -5.34 | -22.56 | -990.00 | -880.00 |
| BasicEPS | -5.34 | -22.56 | -990.00 | -880.00 |
| DilutedNIAvailtoComStockholders | -21.11M | -30.86M | -23.74M | -20.66M |
| NetIncomeCommonStockholders | -21.11M | -30.86M | -23.74M | -20.66M |
| NetIncome | -21.11M | -30.86M | -23.74M | -20.66M |
| NetIncomeIncludingNoncontrollingInterests | -21.11M | -30.86M | -23.74M | -20.66M |
| NetIncomeContinuousOperations | -21.11M | -30.86M | -23.74M | -20.66M |
| PretaxIncome | -21.11M | -30.86M | -23.74M | -20.66M |
| OtherIncomeExpense | -570.00 | -18.68K | ||
| OtherNonOperatingIncomeExpenses | -570.00 | -18.68K | ||
| NetNonOperatingInterestIncomeExpense | 63.57K | 215.11K | 90.10K | 5.13K |
| InterestIncomeNonOperating | 63.57K | 215.11K | 90.10K | 5.13K |
| OperatingIncome | -21.17M | -31.06M | -23.83M | -20.67M |
| OperatingExpense | 21.17M | 31.06M | 23.83M | 20.67M |
| DepreciationAmortizationDepletionIncomeStatement | 6.69K | 15.00K | 25.57K | 22.53K |
| DepreciationAndAmortizationInIncomeStatement | 6.69K | 15.00K | 25.57K | 22.53K |
| DepreciationIncomeStatement | 6.69K | 15.00K | 25.57K | 22.53K |
| ResearchAndDevelopment | 10.54M | 17.62M | 11.51M | 8.97M |
| SellingGeneralAndAdministration | 10.63M | 13.43M | 12.30M | 11.68M |
| GeneralAndAdministrativeExpense | 10.63M | 13.43M | 12.30M | 11.68M |
| OtherGandA | 10.63M | 13.43M | 12.30M | 11.68M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.86M | 1.49M | 1.20M | 1.20M |
| ShareIssued | 10.86M | 1.49M | 1.20M | 1.20M |
| TangibleBookValue | 1.62M | 6.64M | 21.57M | 40.63M |
| InvestedCapital | 1.62M | 7.42M | 22.27M | 41.28M |
| WorkingCapital | -426.70K | 4.28M | 18.66M | 37.55M |
| NetTangibleAssets | 1.62M | 6.64M | 21.57M | 40.63M |
| CommonStockEquity | 1.62M | 7.42M | 22.27M | 41.28M |
| TotalCapitalization | 1.62M | 7.42M | 22.27M | 41.28M |
| TotalEquityGrossMinorityInterest | 1.62M | 7.42M | 22.27M | 41.28M |
| StockholdersEquity | 1.62M | 7.42M | 22.27M | 41.28M |
| RetainedEarnings | -154.80M | -133.69M | -102.83M | -79.09M |
| AdditionalPaidInCapital | 156.41M | 141.10M | 125.10M | 120.32M |
| CapitalStock | 10.86K | 1.49K | 1.20K | 47.87K |
| CommonStock | 10.86K | 1.49K | 1.20K | 47.87K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 2.50M | 3.25M | 2.81M | 1.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.50M | 3.25M | 2.81M | 1.59M |
| OtherCurrentLiabilities | 1.43M | 1.86M | 2.37M | 612.10K |
| PayablesAndAccruedExpenses | 1.07M | 1.40M | 442.93K | 973.20K |
| Payables | 1.07M | 1.40M | 442.93K | 973.20K |
| AccountsPayable | 1.07M | 1.40M | 442.93K | 973.20K |
| TotalAssets | 4.12M | 10.67M | 25.09M | 42.86M |
| TotalNonCurrentAssets | 2.05M | 3.14M | 3.61M | 3.72M |
| OtherNonCurrentAssets | 2.05M | 2.35M | 2.86M | 3.02M |
| NonCurrentPrepaidAssets | 0.00 | 10.00K | 21.82K | 8.69K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 773.48K | 702.10K | 642.36K |
| OtherIntangibleAssets | 773.48K | 702.10K | 642.36K | |
| NetPPE | 0.00 | 7.86K | 23.03K | 48.61K |
| CurrentAssets | 2.08M | 7.53M | 21.47M | 39.14M |
| OtherCurrentAssets | 475.81K | 794.14K | 484.22K | 511.35K |
| PrepaidAssets | 511.35K | |||
| Receivables | 0.00 | 34.85K | 0.00 | |
| AccountsReceivable | 0.00 | 34.85K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 1.60M | 6.74M | 20.95M | 38.63M |
| CashAndCashEquivalents | 1.60M | 6.74M | 20.95M | 38.63M |
| CashFinancial | 1.60M | 20.95M | 38.63M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.15M | -24.81M | -17.68M | -14.37M |
| IssuanceOfCapitalStock | 12.01M | 10.59M | 6.43K | 25.68M |
| CapitalExpenditure | -71.38K | -59.73K | -83.80K | |
| EndCashPosition | 1.60M | 6.74M | 20.95M | 38.63M |
| BeginningCashPosition | 6.74M | 20.95M | 38.63M | 27.32M |
| ChangesInCash | -5.14M | -14.22M | -17.67M | 11.31M |
| FinancingCashFlow | 12.01M | 10.59M | 6.43K | 25.68M |
| CashFlowFromContinuingFinancingActivities | 12.01M | 10.59M | 6.43K | 25.68M |
| NetCommonStockIssuance | 12.01M | 10.59M | 6.43K | 25.68M |
| CommonStockIssuance | 12.01M | 10.59M | 6.43K | 25.68M |
| InvestingCashFlow | 1.17K | -71.21K | -59.73K | -83.80K |
| CashFlowFromContinuingInvestingActivities | 1.17K | -71.21K | -59.73K | -83.80K |
| NetOtherInvestingChanges | 1.00 | 0.38 | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -71.38K | -59.73K | -52.10K |
| SaleOfIntangibles | 157.47K | |||
| PurchaseOfIntangibles | 0.00 | -71.38K | -59.73K | -52.10K |
| NetPPEPurchaseAndSale | 1.17K | 169.00 | 0.00 | -31.70K |
| SaleOfPPE | 1.17K | 169.00 | 0.00 | |
| PurchaseOfPPE | 0.00 | -31.70K | ||
| OperatingCashFlow | -17.15M | -24.74M | -17.62M | -14.28M |
| CashFlowFromContinuingOperatingActivities | -17.15M | -24.74M | -17.62M | -14.28M |
| ChangeInWorkingCapital | -121.08K | 698.13K | 1.36M | 1.01M |
| ChangeInOtherWorkingCapital | 517.45K | 157.47K | ||
| ChangeInOtherCurrentLiabilities | -426.72K | -510.76K | 1.76M | 354.34K |
| ChangeInOtherCurrentAssets | 300.63K | 517.45K | 157.47K | |
| ChangeInPayablesAndAccruedExpense | -323.31K | 954.69K | -530.27K | 780.23K |
| ChangeInPayable | -323.31K | 954.69K | -530.27K | 780.23K |
| ChangeInAccountPayable | -323.31K | 954.69K | -530.27K | 780.23K |
| ChangeInPrepaidAssets | 328.33K | -298.10K | 14.00K | -124.75K |
| ChangeInReceivables | 0.00 | 34.85K | -34.85K | 127.00 |
| ChangesInAccountReceivables | 0.00 | 34.85K | -34.85K | 127.00 |
| OtherNonCashItems | 773.48K | -1.00 | ||
| StockBasedCompensation | 3.30M | 5.41M | 4.73M | 5.35M |
| DepreciationAmortizationDepletion | 6.69K | 15.00K | 25.57K | 22.53K |
| DepreciationAndAmortization | 6.69K | 15.00K | 25.57K | 22.53K |
| Depreciation | 6.69K | 15.00K | 25.57K | 22.53K |
| NetIncomeFromContinuingOperations | -21.11M | -30.86M | -23.74M | -20.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GNPX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|